Referred to the House Committee on Veterans' Affairs.
Requires the VA to designate at least five facilities as "Innovative Therapies Centers of Excellence" to research, educate, and provide specified innovative therapies for listed conditions. Sets designation requirements, creates a peer review panel of experts (exempting it from certain Title 5 provisions), requires annual reports to Veterans’ Affairs committees, and authorizes $30 million per year for research and education activities.
Support for veteran access to psychedelic therapies versus concern about federal endorsement
Relative to its intended legislative type, this bill creates a new statutory program within the Department of Veterans Affairs with multiple specific authorities and some funding, but it leaves several operational, oversight, and safeguard details to administrative discretion.
Requires the VA to designate at least five facilities as "Innovative Therapies Centers of Excellence" to research, educate, and provide specified innovative therapies for listed conditions.
Sets designation requirements, creates a peer review panel of experts (exempting it from certain Title 5 provisions), requires annual reports to Veterans’ Affairs committees, and authorizes $30 million per year for research and education activities.
Defines covered conditions (anxiety, PTSD, chronic pain, depression, Parkinson’s, bipolar disorder, substance use disorder, etc.) and lists specific therapies (MDMA, psilocybin, ketamine, ibogaine, 5-MeO-DMT, etc.).
Program is targeted and administratively plausible, aiding chances, but controversial subject matter and funding dependence limit prospects.
Relative to its intended legislative type, this bill creates a new statutory program within the Department of Veterans Affairs with multiple specific authorities and some funding, but it leaves several operational, oversight, and safeguard details to administrative discretion.
Support for veteran access to psychedelic therapies versus concern about federal endorsement
These are examples from the analysis, not a ranked list of the most-affected groups.
Support for veteran access to psychedelic therapies versus concern about federal endorsement
Likely broadly supportive as a targeted federal investment in veteran mental health and evidence-based psychedelic research.
Views centers as expanding access to promising therapies for hard-to-treat conditions and addressing veteran suicide and addiction concerns.
Cautiously supportive if rigorous scientific safeguards, oversight, and clear budget offsets are present.
Sees potential to improve outcomes but wants demonstration of safety, efficacy, and cost-effectiveness.
Likely skeptical or opposed due to federal promotion of therapies involving federally controlled substances and expanded VA spending.
Worried about federal endorsement of Schedule I drugs and expanded bureaucracy.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Program is targeted and administratively plausible, aiding chances, but controversial subject matter and funding dependence limit prospects.
The bill has not accumulated any surfaced votes yet.
Support for veteran access to psychedelic therapies versus concern about federal endorsement
Program is targeted and administratively plausible, aiding chances, but controversial subject matter and funding dependence limit prospects.
Relative to its intended legislative type, this bill creates a new statutory program within the Department of Veterans Affairs with multiple specific authorities and some funding, but it leaves several operational, over…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.